Transforming and restructuring the nutraceuticals business around healthy life expectancy
First written in FY2016. 8 of 15 entries say "Advanced", first in FY2017. Latest entry: FY2025-H1.
Otsuka Holdings moved to the "Worse" side of this theme in 2025, 2 years after the typical company in this theme (2023).
1 other company's latest entry also says "Reframed".
- FY2025-H1ReframedAnnual report
「In this business, the company conducts R&D on original products that contribute to resolving social issues, leveraging expertise developed in the healthcare business and aiming to help people maintain and improve their health and the well-being of society as a whole.」
The company has explicitly added the well-being of society as a whole and the resolution of social issues to its previous focus on healthy life expectancy and health maintenance. - FY2024-Q1AdvancedAnnual report
「In this business, the company conducts R&D on original products backed by scientific evidence to help people maintain and improve their health, leveraging expertise developed in the healthcare business. Under the SOYJOY brand of soy bars, which provide the nutrition of whole soybeans conveniently and deliciously, it launched SOYJOY Fig & Raisin in March 2024.」
The company continued R&D on health-related products leveraging the healthcare business's expertise and scientific evidence and advanced the commercialisation of new products. - FY2023RestatedAnnual report
「Amid growing health awareness, the nutraceuticals business aims to contribute to extending healthy life expectancy worldwide by leveraging science and expertise developed in the healthcare business to propose solutions based on new concepts for latent needs and social issues, thereby helping people maintain and improve their health.」
The company continues to pursue a policy combining the extension of healthy life expectancy, the science and expertise of its healthcare business, and expansion into new categories and areas. - FY2023-Q2AdvancedAnnual report
「The company launched the new Equelle Jelly in April of the same year under the Equelle brand, which supports women's health and beauty.」
The company advanced new product development leveraging the healthcare business's expertise to help maintain and improve health, including extending healthy life expectancy, and commercialised products including Equelle Jelly. - FY2023-Q1RestatedAnnual report
「In this business, the company conducts R&D on original products backed by scientific evidence to help people maintain and improve their health, leveraging expertise developed in the healthcare business.」
The company continues to pursue a product development policy that leverages the science and expertise of its healthcare business to help maintain and improve health, including extending healthy life expectancy. - FY2022RestatedAnnual report
「Amid growing health awareness, the nutraceuticals business aims to contribute to extending healthy life expectancy worldwide by leveraging science and expertise developed in the healthcare business to propose solutions based on new concepts for latent needs and social issues, thereby helping people maintain and improve their health.」
The company continues to pursue a policy of extending healthy life expectancy and expanding into new categories and areas by leveraging the science and expertise of its healthcare business. - FY2022-Q3AdvancedAnnual report
「In this business, the company conducts R&D on original products backed by scientific evidence to help people maintain and improve their health, leveraging expertise developed in the healthcare business.」
The company continued developing products supported by scientific evidence to maintain and improve health and made concrete progress toward commercialising PMS-related research findings and B240 lactic acid bacteria tablets. - FY2021RestatedAnnual report
「Amid growing health awareness, the nutraceuticals business aims to contribute to extending healthy life expectancy worldwide by leveraging expertise developed in the healthcare business to propose solutions based on new concepts for latent needs and social issues, thereby helping people maintain and improve their health.」
The company continues to pursue a policy of developing new categories and areas by leveraging the healthcare business's expertise, new concepts, and science and technology, with healthy life expectancy as its central theme. - FY2020AdvancedAnnual report
「In March of the same year, the company published research findings in specialist journals on the inhibitory effect of near-infrared light (IRA) on the proliferation of human epidermal cells and the underlying mechanism. In April of the same year, it published research findings on the relationship between hair concerns and equol-producing capacity.」
The company continued R&D on health-related products centred on healthy life expectancy and published research findings on near-infrared light and equol. - FY2020-Q3AdvancedAnnual report
「In March of the same year, the company published research findings in specialist journals on the inhibitory effect of near-infrared light (IRA) on the proliferation of human epidermal cells and the underlying mechanism. In April, it published research findings on the relationship between hair concerns and equol-producing capacity.」
The company continued R&D on health-related products centred on healthy life expectancy and published research findings on near-infrared light and equol in specialist journals. - FY2018AchievedAnnual report
「As a result of fundamental reform of its earnings structure, the company achieved its initial plans for both revenue and operating profit and brought forward achievement of the plan's key target, an operating margin of more than 10%.」
The company states that it achieved an operating margin of more than 10% ahead of schedule as a target of its Second Mid-term Management Plan, through new product development and launches focused on extending healthy life expectancy, global expansion of core brands, and a review of management assets supporting the value chain. - FY2018-Q3AdvancedAnnual report
「In addition, Pocari Sweat, which communicates the importance of replenishing fluids and electrolytes, launched Ice Slurry, a new formulation focused on core body temperature and designed to cool the body from within as a heatstroke-prevention measure, through the company's mail-order service in July of the same year.」
The company continued R&D and new product development centred on healthy life expectancy and launched a new dosage form for heatstroke prevention. - FY2018-Q2AdvancedAnnual report
「Within its SOYJOY soy bar range, the company launched the new flavour SOYJOY Crispy Banana in March 2018 and SOYJOY Crispy Peach in June of the same year.」
The company continued R&D and new product development centred on healthy life expectancy and launched new SOYJOY flavours and Equelle Jelly. - FY2017AdvancedAnnual report
「The company will focus on accelerating R&D under the theme of healthy life expectancy and on promotional activities that communicate product value, while developing new products.」
The company continues R&D centred on healthy life expectancy, product-value-focused promotion, and new product development, and describes specific progress including foods with function claims and collaborative research courses on women's health. - FY2016First statedAnnual report
「The company will focus on accelerating R&D under the theme of healthy life expectancy and on promotional activities that communicate product value, while developing new products.」
The company presented for the first time a business transformation policy combining R&D, promotion, new product development, and a review of the value chain, with healthy life expectancy as an explicit theme.